Research funder · United States

Michael J. Fox Foundation for Parkinson's Research

Non-profit organization in the USA

michaeljfox.org

Grants since 2016: 1 275
Awarded, last 5 years (where amounts are published): —
Funded works, last 5 years: 3 085
Funded works, all time: 6 716

Grants

2017 · research · Improved Biomarkers and Clinical Outcome Measures

Developing Biosignatures of Parkinson's Disease Using Sense of Smell

Charlotte D'Hulst · Yesse Technologies, Inc.

2017 · research · Research Grant

Identification and Optimization of beta-Glucocerebrosidase Modulators for Parkinson's Disease

Jianbin Zheng · Northwestern University

2017 · research · LRRK2 Biology Consortium

Study of How LRRK2 Mutations Affect Cellular Processes that Could Lead to PD

Scott F. Sneddon · Sharp Edge Labs, Inc.

2017 · research · Research Grant

T Cell-mediated Autoimmune Responses in Parkinson's Disease

David Sulzer · Research Foundation For Mental Hygiene/ New York State Psychiatric Institute/ Columbia University

2017 · research · Target Advancement Program

Preventing Misfolded Alpha-synuclein Accumulation

Caryl E. Sortwell · Michigan State University

2017 · research · Research Grant

Gene Therapy to Restore Protein Imbalance in Parkinson's Disease

Claudio Hetz Flores · University of Chile

2017 · research · Target Advancement Program

Investigating Kainate Receptor as a Potential Target to Protect against Early-Onset Parkinson's Disease

Jenny Sassone · Vita-Salute San Raffaele University

2017 · research · Therapeutic Pipeline Program

Advancing Neuroprotective Protein Regulators Toward the Clinical Candidate Phase

Robert Lutjens · Addex Therapeutics (Switzerland)

2017 · research · LRRK2 Therapeutic and Safety Initiative

Using Organs-on-Chips to Test the Safety of New Drugs for Parkinson's Disease

Remi Villenave · Emulate, Inc

2017 · research · Target Advancement Program

Neuroprotective Effects of Endosulfine-alpha in Parkinson's Disease

Jason R. Cannon · Purdue University West Lafayette

2017 · research · Therapeutic Pipeline Program

Cell-Permeable Parkin Protein Suppresses Parkinson's Disease-associated Symptoms

Daewoong Jo · Cellivery Therapeutics, Inc.

2017 · research · LRRK2 Biology Consortium

Describing the Structure and Function of LRRK2

Susan S. Taylor · University of California San Diego

2017 · research · Access to Data and Biospecimens

An 8-protein panel for diagnosis of Parkinson’s Disease: Sample request for replication in PDBP and PPMI

Alice Chen-Plotkin · University Of Pennsylvania (perelman School Of Medicine)

2017 · research · Research Grant

Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease

Tanya Simuni · Northwestern University

2017 · research · LRRK2 Biology Consortium

How Does LRRK2 Activity Affect Inflammatory Signaling in Parkinson's Disease?

Nicolas Dzamko · The University of Sydney

2017 · research · LRRK2 Biology Consortium

Characterization of Leukocytes as Biomarkers for LRRK2 and Autophagy in Parkinson's Disease

Fernando Macian · Albert Einstein College of Medicine

2017 · research · Target Advancement Program

Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release

Martin B. Gill · Libra Therapeutics, Inc.

2017 · research · Therapeutic Pipeline Program

Alternative Brain Stimulation Approach for the Treatment of Swallowing Impairment in Parkinson’s Disease

Daniel Weiss · Centre For Neurology, Department For Neurodegenerative Diseases And Hertie Institute For Clinical Br

2017 · research · LRRK2 Biology Consortium

Developing a LRRK2-deactivating Vitamin for the Treatment of Parkinson’s Disease

Iban Ubarretxena · Icahn School of Medicine at Mount Sinai

2017 · research · Research Grant

Inflammation in Parkinson's Disease

Nicolas Dzamko · The University of Sydney

2017 · research · Research Grant

Using Deep Brain Stimulation to Understand and Treat Dystonia Associated with Parkinson’s Disease

Harrison C. Walker · University of Alabama at Birmingham

2017 · research · LRRK2 Biology Consortium

Kinase Activity-mediated Changes in LRRK2-Parkinson's and Sporadic Parkinson's Cells and Rab Protein Function

Sabine Hilfiker · Rutgers, The State University of New Jersey

2017 · research · Research Grant

Optimization of Dopamine Compounds for the Treatment of L-DOPA-induced Dyskinesias (LIDs)

Corey R. Hopkins · University of Nebraska Medical Center

2017 · research · Research Grant

Development of Analytic Tests to Use as Nilotinib Companion Diagnostics in Parkinson's Disease

David R. Walt · Harvard University

2017 · research · Improved Biomarkers and Clinical Outcome Measures

Neuron-restricted RNA Profiles in the Plasma of Those with Genetic and Sporadic Parkinson's Disease

Leonidas Stefanis · University Of Athens Medical School And Biomedical Research Foundation Of The Academy Of Athens

2017 · research · LRRK2 Therapeutic and Safety Initiative

Genetic and Clinical Basis for Inflammatory Bowel Disease and Parkinson's Disease Comorbidity

Inga Peter · Icahn School of Medicine at Mount Sinai

2017 · research · Research Grant

Promoting Mitochondrial Transport in Dopaminergic Neurons

Thomas L. Schwarz · Harvard University

2017 · research · Research Grant

A Study of Gastrointestinal Impairment in Parkinson's Disease

William L. Hasler · Michigan Medicine

2017 · research · Improved Biomarkers and Clinical Outcome Measures

Using Automatic Acoustic Speech Analysis and REM Sleep Behavior Disorder to Detect Individuals at High Risk of Parkinson's Disease and Other Alpha-synucleinopathies

Jan Rusz · Czech Technical University in Prague

2017 · research · Target Advancement Program

Disruption of Pathological Protein-protein Interactions in Alpha-synuclein

Jonathan Nathanial Sachs · University of Minnesota

2017 · research · Computational Science

Software for the Analysis of Data on Parkinson's Disease Symptoms Collected Using Wearable Technology

George Roussos · Birkbeck, University of London

2017 · research · Research Grant

Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)

Christopher G. Tarolli · University of Rochester Medicine

2017 · research · LRRK2 Therapeutic and Safety Initiative

The Effects of a LRRK2 Inhibitor on Alpha-synuclein-induced Dopamine Deficits in a Pre-clinical Model of Parkinson's Disease

James B. Koprich · Atuka, Inc.

2017 · research · Research Grant

Studying the Parkin Protein in New Pre-Clinical Models

Ian G. Ganley · University of Dundee

2017 · research · LRRK2 Biology Consortium

LRRK2 Activity and Dyskinesia

Roberta Marongiu · Weill Cornell Medicine

2017 · research · Research Grant

Validation of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) for Parkinson's Disease

Daniel Weintraub · University of Pennsylvania

2017 · research · LRRK2 Therapeutic and Safety Initiative

Efficacy and Safety of Chronic Treatment with LRRK2 Inhibitors

Robert Hodgson · Charles River Discovery

2017 · research · Target Advancement Program

Validation of USP30 as a Therapeutic Target for Parkinson's Disease Modification

Paul Thompson · Mission Therapeutics

2017 · research · Research Grant

The RESISTA-PD trial - The Effects of Resistant Starch on Bowel Habits, Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease

Marcus M. Unger · Saarland University, Department Of Neurology

2017 · research · Target Advancement Program

Activation of PINK1/Parkin-mediated Mitochondrial Quality Control

Marius K. Lemberg · Heidelberg University